$ARQT

Arcutis Biotherapeutics, Inc.

Arcutis is a commercial-stage biopharmaceutical company that develops and commercializes treatments for dermatological diseases, including immune-mediated conditions. Its marketed portfolio centers on ZORYVE, a topical roflumilast product available as creams and foam for plaque psoriasis, seborrheic dermatitis and atopic dermatitis. The products are approved for use in the United States, and several are also approved in Canada. Arcutis earns money from commercializing ZORYVE and licenses topical roflumilast to partners for Greater China and Southeast Asia and Japan. Its pipeline includes ARQ-234, a fusion protein being developed for atopic dermatitis and potentially other inflammatory conditions, as well as ZORYVE studies in additional dermatological indications. Arcutis is headquartered in Westlake Village, California.

No enriched coverage for $ARQT in the last 7 days.

—
$1.7M
Matsuda Masaru
60%
See all $ARQT insider activity →

Key facts: NASDAQ:ARQT Starts Phase 3 Trial; Target Rises to $39.62

Arcutis Biotherapeutics (ARQT) began a Phase 3 trial for its ZORYVE cream to treat atopic dermatitis. The company's average 12-month price target increased to $39.62, suggesting 16% upside from its Nov. 4 close, with seven Buy and one Hold ratings.

ARQT sentiment & insider activity

Recent ARQT coverage spans financial news, earnings and insider activity.

In the last 30 days, ARQT insiders filed 5 SEC Form 4 transactions — no purchases and 5 sales ($1.7M). The most active reporter was Matsuda Masaru, EVP, Chief Legal Officer, with 2 filings. 60% of those filings were made under pre-arranged Rule 10b5-1 plans.

What's driving ARQT

  • Positive trial data may lift ARQT as investors anticipate FDA approval.

    tradingview.com · Nov 13, 2026

  • Positive clinical milestone and higher price target suggest upside pressure.

    tradingview.com · Nov 6, 2026

  • TD Cowen kept its Buy rating on Arcutis Biotherapeutics and increased its price target to $40 from $35, citing a 17.5% upside from the Nov 4 close of $34.05.

    tradingview.com · Nov 5, 2026

  • Earnings miss drives sell pressure.

    seekingalpha.com · Nov 5, 2026

  • Arcutis Biotherapeutics, Inc. saw its average price target raised by analysts from $39.12 to $39.75, with a range of $34 to $48. This implies a 17% upside from the Nov. 4 closing price. The consensus rating remains 'Buy' among 8 analysts, with 7 Buys, 1 Hold, and 0 Sells.

    tradingview.com · Nov 5, 2026

AlphAI scores every news story that mentions ARQT with an AI model for sentiment and relevance, and aggregates insider trades from Arcutis Biotherapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $ARQT

Score
$ARQTHighAI 8/10Earnings

Arcutis Announces Third Quarter 2026 Financial Results and Provides Business Update

Arcutis Biotherapeutics, Inc. (ARQT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Arcutis Announces Third Quarter 2026 Financial Results and Provides Business Update • Continued strong ZORYVE® (roflumilast) net product revenue growth, with Q3 revenues of $143.9 million, +45% versus Q3 of 2025, and +11% versus Q2 of 2026, driven by strong demand growth • Raised

Related tickers